Inozyme Pharma Inc. – Material Contracts Watch

from 8-K 14 pages Tender and Support Agreement

from 10-K 3 pages Payment 1 (Signing of Contract) $80,789 Payment 2 (April 1, 2025) $80,789 Payment 3 (July 1, 2025) $80,789 Payment 4 (October 1, 2025) $80,789 Total $323,156

from 10-K 3 pages Inozyme Pharma, Inc. Non-Employee Director Compensation Policy

from 10-Q 3 pages Inozyme Pharma, Inc. Non-Employee Director Compensation Policy

from 10-K 6 pages Inozyme Pharma, Inc. Restricted Stock Unit Agreement Granted Under 2020 Stock Incentive Plan

from 10-K 25 pages Certain Identified Information Has Been Marked in the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Inozyme Pharma, Inc. Confidential Yale University Corporate Sponsored Research Agreement

from 10-Q 6 pages Inozyme Pharma, Inc. Restricted Stock Unit Agreement Granted Under 2023 Inducement Stock Incentive Plan

from 10-Q 5 pages Inozyme Pharma, Inc. Nonstatutory Stock Option Agreement Granted Under 2023 Inducement Stock Incentive Plan

from 10-Q 3 pages Inozyme Pharma, Inc. Non-Employee Director Compensation Policy

from 10-Q 13 pages Material contract

from 10-Q 10 pages Consulting Agreement

from 10-Q 13 pages As We Have Discussed, You Are Retiring and Resigning From Employment With Inozyme Pharma Switzerland Gmbh (The “Company”), Effective April 30, 2023 (The “Separation Date”). by Countersigning and Returning This Letter Agreement, You Will Be Entering Into a Binding Agreement With the Company and Will Be Agreeing to the Terms and Conditions Set Forth in the Numbered Paragraphs Below, Including the Release of Claims Set Forth in Paragraph 3. the Severance Benefits Described in Paragraph 2 Below Will Be Subject to You Adhering to This Letter Agreement and Returning a Signed Waiver in the Form of Annex 1 on but Not Earlier Than May 31, 2023 and Not Revoking Your Agreement to the Waiver in Annex 1 (As Described Below) During the Seven (7) Day Period After You Have Signed or Timely Revoking Paragraph 4(b) Below, in Either Case by Notifying Me in Writing. Although Your Receipt of the Severance Benefits Is Expressly Conditioned on You Entering Into This Letter Agreement and Annex 1 and Not Revoking Annex 1 or Paragraph 4(b), the Following Will Apply Regardless of Whether or Not You Do So

from 10-Q 14 pages March 21, 2023 Doug Treco [**]

from 8-K 8 pages Consulting Agreement

from 8-K 13 pages Executive Transition, Separation, and Release of Claims Agreement

from 10-Q 23 pages Certain Identified Information Has Been Marked in the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Inozyme Pharma, Inc. Confidential Yale University Corporate Sponsored Research Agreement

from 10-Q 57 pages Agreement

from 10-Q 13 pages March 2, 2022 Sanjay S. Subramanian

from 10-K 11 pages Consulting Agreement

from 10-K 20 pages Via Electronic Mail November 3, 2021 (As Revised on November 30, 2021) Deborah Wenkert, MD [**] Dear Deb